AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

NIH

Appreciating Dr. Jack Whitescarver’s Many Contributions to HIV/AIDS Research

photo whitescarver

At the end of this month, we bid a fond farewell to a colleague who has played a key role in leading Federal research efforts in response to HIV/AIDS since the earliest days of the epidemic. As NIH previously announced, on July 1, 2015, Dr. Jack Whitescarver is retiring and stepping down as NIH’s Associate…

Funding Available from NIH’s HIV/AIDS Community Information Outreach Project

NIH_NLM_BLU_VERT_4 (1)

NIH’s National Library of Medicine (NLM) has announced the solicitation of quotations from organizations and libraries to design and conduct projects for improving HIV/AIDS information access for patients and the affected community as well as their caregivers and the general public. Awards of up to $50,000 are available. Applications are due by July 20, 2015….

Curing Hard-to-Treat Hepatitis C

hepc_crop

In a new video, NIH researchers and their colleagues from health centers in the District of Columbia discuss efforts to improve treatments for hepatitis C, a potentially life-threatening viral disease that slowly damages the liver. NIH-sponsored clinical studies in the nation’s capital focus on identifying effective, safe, and convenient therapies for hard-to-treat hepatitis C patients,…

A Conversation with Dr. Anthony Fauci: Results from the START Trial and Implications for the Global Treatment of HIV

Anthony Fauci

Last week, NIH’s National Institute of Allergy and Infectious Diseases (NIAID) released the exciting results of the Strategic Timing of Antiretroviral Treatment (START) study, a randomized, controlled clinical trial to more clearly define the optimal time and benefits for people with HIV to begin antiretroviral therapy (ART). Given the implications of the study, AIDS.gov sat…

International Study Demonstrates Benefits of Early HIV Treatment

Dr. Anthony Fauci

The question of when to initiate antiretroviral therapy (ART) during the course of HIV infection has been debated for years, yet a conclusive answer has remained elusive. For HIV-infected individuals the primary question was whether to start ART early, risking possible cumulative drug toxicities, potential viral resistance, and difficulties with long-term adherence, or to defer…

Starting antiretroviral treatment early improves outcomes for HIV-infected individuals

nih logo

For Immediate Release: Wednesday, May 27, 2015 NIH-funded trial results likely will impact global treatment guidelines A major international randomized clinical trial has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner, when their CD4+ T-cell count—a key measure of immune…

BULLETIN: HIV Vaccine Awareness Day 2015

nih logo

May 18, 2015 Vaccination has historically been the best method for protecting against and ultimately defeating mankind’s most devastating infectious diseases. Although the path to developing a safe and effective HIV vaccine has so far been difficult, achieving this goal remains key to realizing a durable end to the global HIV/AIDS pandemic. HIV vaccine development…

New! NIH Clinical Trials Media Player Now Available

NIH media player

Clinical Trials Clinical trials play an immensely important role in finding medical advancements and developing treatments for many diseases and conditions, including HIV. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving quality…